Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.

Research by University of Sydney scientists has uncovered a mechanism that may explain why glioblastoma returns after ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would ...

A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...

To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

Sarepta Therapeutics (SRPT) has quietly staged a sharp rebound over the past month, even though the longer term chart still looks bruised. That mix of momentum and past damage naturally raises ...